MCID: EWN003
MIFTS: 68

Ewing Sarcoma

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Bone diseases, Cancer diseases, Eye diseases

Aliases & Classifications for Ewing Sarcoma

MalaCards integrated aliases for Ewing Sarcoma:

Name: Ewing Sarcoma 57 12 53 25 59 75 13 15
Neuroepithelioma 57 76 53 59 55 73
Ewing's Sarcoma 76 53 25 37 29
Ewing's Tumor 12 53 25 75
Ewings Sarcoma 12 55 73
Eye Diseases 55 43 44
Localized Peripheral Primitive Neuroectodermal Tumor 12 73
Ewings Sarcoma-Primitive Neuroectodermal Tumor 12 73
Peripheral Primitive Neuroectodermal Tumor 12 59
Peripheral Neuroepithelioma 75 55
Abnormality of the Eye 29 6
Sarcoma, Ewing's 53 40
Askin Tumor 75 44
Eye Disease 12 15
Ewing Tumor 53 25
Es 57 75
Localized Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Extraosseous Ewings Sarcoma-Primitive Neuroepithelial Tumor 73
Ewing's Sarcoma/peripheral Primitive Neuroectodermal Tumor 12
Neuroectodermal Tumors, Primitive, Peripheral 44
Neuroectodermal Tumor, Primitive 73
Pnet of Thoracopulmonary Region 12
Primitive Neuroectodermal Tumor 75
Ewing's Family Localized Tumor 12
Ewing Sarcoma Family of Tumors 75
Neuroepithelioma, Peripheral 73
Localized Ewing's Sarcoma 12
Tumor of the Ewing Family 25
Extraosseous Ewing Tumor 75
Localized Ewing Sarcoma 12
Localized Ewing's Tumor 12
Ewing Family of Tumors 25
Pnet of the Chest Wall 75
Peripheral Pnet 59
Disorder of Eye 73
Sarcoma, Ewing 44
Askin's Tumor 73
Ppnet 59
Pnet 75
Esft 75
Pne 75

Characteristics:

Orphanet epidemiological data:

59
ewing sarcoma
Inheritance: Not applicable; Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;
neuroepithelioma
Inheritance: Not applicable; Age of onset: Childhood;

HPO:

32
ewing sarcoma:
Inheritance somatic mutation


Classifications:



Summaries for Ewing Sarcoma

Genetics Home Reference : 25 Ewing sarcoma is a cancerous tumor that occurs in bones or soft tissues, such as cartilage or nerves. There are several types of Ewing sarcoma, including Ewing sarcoma of bone, extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), and Askin tumor. These tumors are considered to be related because they have similar genetic causes. These types of Ewing sarcoma can be distinguished from one another by the tissue in which the tumor develops. Approximately 87 percent of Ewing sarcomas are Ewing sarcoma of bone, which is a bone tumor that usually occurs in the thigh bones (femurs), pelvis, ribs, or shoulder blades. Extraosseous (or extraskeletal) Ewing sarcoma describes tumors in the soft tissues around bones, such as cartilage. pPNETs occur in nerve tissue and can be found in many parts of the body. A type of pPNET found in the chest is called Askin tumor.

MalaCards based summary : Ewing Sarcoma, also known as neuroepithelioma, is related to extraskeletal ewing sarcoma and bone ewing's sarcoma, and has symptoms including eye manifestations, pain in or around eye and redness or discharge of eye. An important gene associated with Ewing Sarcoma is EWSR1 (EWS RNA Binding Protein 1), and among its related pathways/superpathways are Transcriptional misregulation in cancer and NF-kappaB Signaling. The drugs Erbitux and Evista have been mentioned in the context of this disorder. Affiliated tissues include bone, eye and lung, and related phenotypes are ewing's sarcoma and Increased shRNA abundance (Z-score > 2)

Disease Ontology : 12 A bone cancer that has_material_basis in neural crest cells derives from undeveloped, undifferentiated neuroectoderm.

NIH Rare Diseases : 53 Ewing sarcoma is a malignant (cancerous) bone tumor that affects children. It can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. The tumor may arise anywhere in the body, usually in the long bones of the arms and legs, the pelvis, or the chest. It may also develop in the skull or the flat bones of the trunk. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Fever may also be present. The tumor often spreads (metastasis) to the lungs and other bones. The cause of Ewing sarcoma is unknown. Most cases are thought to occur randomly and many involved a reciprocal translocation between chromosomes 11 and 22. Treatment depends upon a number of factors, but may include chemotherapy, radiation and/or surgical interventions.

OMIM : 57 The Ewing sarcoma family of tumors (primitive neuroectodermal tumors; PNET) comprise morphologically heterogeneous tumors that are characterized by nonrandom chromosomal translocations involving the EWS gene on chromosome 22q12 and one of several members of the ETS family of transcription factors. The tumors include Ewing sarcoma, peripheral neuroepithelioma, and Askin tumor. In approximately 90% of cases of ESFT, the FLI1 gene (193067) on chromosome 11 is the fusion partner of EWS; in approximately 10%, the EWS fusion partner is the ERG gene (165080) on chromosome 22. Many other ETS family members have been identified as fusion partners of EWS, but these cases are rare (Khoury, 2005). (612219)

MedlinePlus : 43 Some eye problems are minor and don't last long. But some can lead to a permanent loss of vision. Common eye problems include Refractive errors Cataracts - clouded lenses Optic nerve disorders, including glaucoma Retinal disorders - problems with the nerve layer at the back of the eye Macular degeneration - a disease that destroys sharp, central vision Diabetic eye problems Conjunctivitis - an infection also known as pinkeye Your best defense is to have regular checkups, because eye diseases do not always have symptoms. Early detection and treatment could prevent vision loss. See an eye care professional right away if you have a sudden change in vision, if everything looks dim, or if you see flashes of light. Other symptoms that need quick attention are pain, double vision, fluid coming from the eye, and inflammation. NIH: National Eye Institute

UniProtKB/Swiss-Prot : 75 Ewing sarcoma: A highly malignant, metastatic, primitive small round cell tumor of bone and soft tissue that affects children and adolescents. It belongs to the Ewing sarcoma family of tumors, a group of morphologically heterogeneous neoplasms that share the same cytogenetic features. They are considered neural tumors derived from cells of the neural crest. Ewing sarcoma represents the less differentiated form of the tumors.

Wikipedia : 76 Ewing\'s sarcoma or Ewing sarcoma (/ˈjuːɪŋ/) is a malignant small, round, blue cell tumor. It is a rare... more...

Related Diseases for Ewing Sarcoma

Diseases related to Ewing Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 195)
# Related Disease Score Top Affiliating Genes
1 extraskeletal ewing sarcoma 36.3 CD99 ENO2 ERG EWSR1 FLI1 FUS
2 bone ewing's sarcoma 34.6 CD99 ENO2 EWSR1 PTPRC WT1
3 extraosseous ewing's sarcoma 34.4 CD99 ENO2 ETV4 EWSR1
4 sarcoma 34.3 ERG EWSR1 FLI1 FUS KIT
5 askin's tumor 33.8 ENO2 EWSR1
6 ewing's family of tumors 33.4 EWSR1 FLI1 KIT
7 rhabdomyosarcoma 32.6 ENO2 EWSR1 IGF1R PTPRC
8 desmoplastic small round cell tumor 32.5 ENO2 EWSR1 WT1
9 rhabdomyosarcoma 2 32.3 ENO2 EWSR1 IGF1R WT1
10 retinal disease 32.3 ABCC6 CNGA3 RDH12
11 olfactory neuroblastoma 32.3 ENO2 EWSR1 PTPRC
12 rhabdoid cancer 32.2 IGF1R PTPRC WT1
13 clear cell sarcoma 32.2 ENO2 EWSR1 FUS KIT WT1
14 leukemia, acute myeloid 31.9 KIT NCAM1 PTPRC WT1
15 merkel cell carcinoma 31.9 ENO2 KIT NCAM1
16 fish-eye disease 12.3
17 aland island eye disease 12.3
18 bornholm eye disease 12.2
19 extraosseous ewings sarcoma-primitive neuroepithelial tumor 12.1
20 soft tissue peripheral neuroepithelioma 12.0
21 bone peripheral neuroepithelioma 12.0
22 dissociative seizures 11.9
23 kidney rhabdoid cancer 11.8 CD99 ENO2 EWSR1 PTPRC WT1
24 connective tissue cancer 11.8 CD99 ENO2 EWSR1 FUS KIT
25 myxoid liposarcoma 11.7 ERG EWSR1 FUS IGF1R
26 cell type cancer 11.7 ENO2 EWSR1 KIT POU5F1
27 teratoma 11.7 CD99 ENO2 KIT POU5F1
28 muscle cancer 11.7 ENO2 EWSR1 KIT WT1
29 histiocytoma 11.7 EWSR1 FUS KIT PTPRC
30 chondrosarcoma, extraskeletal myxoid 11.7 ENO2 EWSR1 FUS WT1
31 endometrial small cell carcinoma 11.7 ENO2 KIT NCAM1 PTPRC
32 malignant mesenchymoma 11.7 EWSR1 KIT NCAM1 WT1
33 small cell carcinoma 11.7 ENO2 KIT NCAM1 PTPRC
34 pancreatic neuroendocrine tumor 11.6
35 testicular infarct 11.6 KIT POU5F1 PTPRC
36 cauda equina neoplasm 11.6 ENO2 EWSR1 WT1
37 extraosseous chondrosarcoma 11.6 ENO2 EWSR1 FUS
38 conventional fibrosarcoma 11.6 ENO2 KIT PTPRC
39 orbital cancer 11.6 ENO2 EWSR1 NCAM1
40 cutaneous ganglioneuroma 11.6 ENO2 KIT NCAM1
41 gastric small cell carcinoma 11.6 ENO2 NCAM1 PTPRC
42 heart sarcoma 11.6 ENO2 KIT WT1
43 angiomyoma 11.6 ENO2 KIT NCAM1
44 nervous system cancer 11.6 CD99 ENO2 EWSR1
45 malignant skin fibrous histiocytoma 11.6 CD99 KIT NCAM1
46 dysgerminoma of ovary 11.6 ENO2 KIT WT1
47 rete testis neoplasm 11.6 ENO2 KIT NCAM1
48 myeloid sarcoma 11.6 KIT NCAM1 PTPRC
49 bladder sarcoma 11.6 CD99 EWSR1
50 malignant dermis tumor 11.6 CD99 KIT NCAM1

Graphical network of the top 20 diseases related to Ewing Sarcoma:



Diseases related to Ewing Sarcoma

Symptoms & Phenotypes for Ewing Sarcoma

Clinical features from OMIM:

612219

Human phenotypes related to Ewing Sarcoma:

32
# Description HPO Frequency HPO Source Accession
1 ewing's sarcoma 32 HP:0012254

UMLS symptoms related to Ewing Sarcoma:


eye manifestations, pain in or around eye, redness or discharge of eye, pathological conditions, signs and symptoms, lid retraction, visual disturbance, fever

GenomeRNAi Phenotypes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

26 (show all 28)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.87 WT1
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 9.87 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.87 EWSR1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.87 WT1
5 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.87 EWSR1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.87 EWSR1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.87 EWSR1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.87 EWSR1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.87 IMPG2
10 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.87 KIT WT1 EWSR1 IMPG2
11 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.87 KIT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.87 EWSR1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.87 IMPG2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.87 KIT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.87 IMPG2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-19 9.87 EWSR1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.87 WT1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.87 WT1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.87 KIT WT1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.87 WT1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-42 9.87 KIT EWSR1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.87 WT1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.87 WT1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.87 EWSR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.87 EWSR1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.87 KIT WT1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.87 KIT
28 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.87 KIT EWSR1

MGI Mouse Phenotypes related to Ewing Sarcoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.9 ENO2 ERG ETV1 FLI1 IGF1R KIT
2 neoplasm MP:0002006 9.5 IGF1R KIT PTPRC WT1 ERG ETV4
3 nervous system MP:0003631 9.4 CNGA3 ENO2 ERG ETV1 ETV4 FLI1

Drugs & Therapeutics for Ewing Sarcoma

FDA approved drugs:

(show all 6)
# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Erbitux 18 49 CETUXIMAB Imclone, Bristol-Myers Squibb February 2004
2
Evista 18 49 RALOXIFENE HYDROCHLORIDE Eli Lilly September 2007
3
Istodax 18 49 ROMIDEPSIN Gloucester Pharmaceuticals November 2009
4
Treanda 18 49 BENDAMUSTINE HYDROCHLORIDE Cephalon October 2008
5
Afinitor 18 49 EVEROLIMUS Novartis March 2009
6
Sutent 18 49 SUNITINIB MALATE Pfizer May 2011/ January 2006

Drugs for Ewing Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
3
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
4
Carboplatin Approved Phase 3,Phase 1,Phase 2,Not Applicable 41575-94-4 10339178 498142 38904
5
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
6
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
7
Mesna Approved, Investigational Phase 3,Phase 2,Phase 1 3375-50-6 598
8
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
9
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
10
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
11
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
12
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 2019 457193
13
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 119413-54-6, 123948-87-8 60700
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
15
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
16
Zoledronic acid Approved Phase 3,Phase 1 118072-93-8 68740
17
Cyproheptadine Approved Phase 3 129-03-3 2913
18
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
19
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21
Treosulfan Investigational Phase 3 299-75-2 9296
22 Deslorelin Investigational, Vet_approved Phase 2, Phase 3 57773-65-6
23
Cobalt Phase 3,Phase 2 7440-48-4 104729
24 razoxane Phase 3,Phase 2
25
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
26 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 topoisomerase I inhibitors Phase 3,Phase 1,Phase 2,Not Applicable
28 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1,Not Applicable
29 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
30 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
31 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
32 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
33 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
34 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
35 Etoposide phosphate Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
38 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
40 Antirheumatic Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
42 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
43 Antineoplastic Agents, Hormonal Phase 2, Phase 3,Phase 1
44 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics Phase 3,Phase 2,Phase 1
46 Central Nervous System Depressants Phase 3,Phase 1
47 Adjuvants, Anesthesia Phase 3
48 Narcotics Phase 3
49 Analgesics, Opioid Phase 3
50 Anesthetics Phase 3

Interventional clinical trials:

(show top 50) (show all 264)
# Name Status NCT ID Phase Drugs
1 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
2 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
3 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
4 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
6 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
7 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
8 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
9 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
10 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide;ifosfamide;etoposide;topotecan hydrochloride
11 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
12 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Not yet recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
13 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
14 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
15 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
16 Study of Intensive Chemotherapy, Surgery and Radiotherapy to Treat Ewing's Sarcoma in Children and Young Adults Unknown status NCT01696669 Phase 2 Chemotherapy
17 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
18 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
19 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
20 Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases Unknown status NCT00084695 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;melphalan;methylprednisolone
21 Olaparib in Adults With Recurrent/Metastatic Ewing's Sarcoma Completed NCT01583543 Phase 2 Olaparib
22 Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Completed NCT02546544 Phase 2 Linsitinib
23 Study Of CP-751,871 In Patients With Ewing's Sarcoma Family Of Tumors Completed NCT00560235 Phase 1, Phase 2 CP-751,871
24 Vinblastine, Celecoxib, and Combination Chemotherapy in Treating Patients With Newly-Diagnosed Metastatic Ewing's Sarcoma Family of Tumors Completed NCT00061893 Phase 2 celecoxib;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vinblastine sulfate;vincristine sulfate;MESNA;Filgrastim
25 Aerosol L9-NC and Temozolomide in Ewing's Sarcoma Completed NCT00492141 Phase 1, Phase 2 Temozolomide;L9-NC
26 Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma Completed NCT00470275 Phase 2 cytarabine
27 Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma Completed NCT00276692 Phase 2 irinotecan hydrochloride
28 Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma Completed NCT00516295 Phase 2 topotecan hydrochloride;vincristine sulfate;cyclophosphamide
29 New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and Neuroblastoma Completed NCT00001335 Phase 2 ADR-529;Topotecan;G-CSF
30 Combination Chemotherapy and Biological Therapy in Treating Patients With High-Risk Ewing's Sarcoma Completed NCT00003667 Phase 2 cyclophosphamide;dexrazoxane hydrochloride;disaccharide tripeptide glycerol dipalmitoyl;doxorubicin hydrochloride;vincristine sulfate
31 Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma Completed NCT00073983 Phase 2 docetaxel;gemcitabine hydrochloride
32 Combination Chemotherapy in Treating Patients With Newly Diagnosed Metastatic Ewing's Sarcoma or Primitive Neuroectodermal Tumor Completed NCT00002643 Phase 2 amifostine trihydrate;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
33 Holmium Ho 166 DOTMP Followed by Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Ewing's Sarcoma or Rhabdomyosarcoma That Has Spread to the Bone Completed NCT00006234 Phase 1, Phase 2
34 Exatecan Mesylate in Treating Patients With Ewing's Sarcoma, Primitive Neuroectodermal Tumor, or Desmoplastic Small Round Cell Tumor Completed NCT00055952 Phase 2 exatecan mesylate
35 Study of Zalypsis® (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy Completed NCT01222767 Phase 2 Zalypsis
36 Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors Completed NCT00357396 Phase 2 busulfan;melphalan;thiotepa
37 Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer Completed NCT00002466 Phase 2 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
38 Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor Completed NCT00062205 Phase 2 imatinib mesylate
39 Trabectedin in Treating Young Patients With Recurrent or Refractory Soft Tissue Sarcoma or Ewing's Family of Tumors Completed NCT00070109 Phase 2 trabectedin
40 Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma Completed NCT00923351 Phase 1, Phase 2 Tumor Purged/CD25 Depleted Lymphocytes;rhIL-7
41 A Five-Tier, Open-Label Study of IMC-A12 in Advanced Sarcoma Completed NCT00668148 Phase 2
42 A Study of R1507 in Participants With Recurrent or Refractory Sarcoma Completed NCT00642941 Phase 2 RG1507
43 A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric Sarcomas Completed NCT00001566 Phase 2 indinavir sulfate
44 A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric Sarcomas Completed NCT00001564 Phase 2 EF-1 Peptide;EF-2 Peptide;PXFK Peptide;E7 Peptide;IL-2;IL-4;GM-CSF;CD40 Ligand
45 A Study of Pemetrexed in Children With Recurrent Cancer Completed NCT00520936 Phase 2 pemetrexed
46 Intensive Chemo-Radiotherapy With Peripheral Blood Progenitor Cell Rescue for Children With Advanced Neuroblastoma and Sarcomas Completed NCT00165139 Phase 2 Vincristine;Cyclophosphamide;Adriamycin;Etoposide (VP-16);Cisplatin;Carboplatin;Melphalan;Ifosfamide;G-CSF (granulocyte-colony stimulating factor);Mesna
47 A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone Completed NCT01288573 Phase 1, Phase 2 plerixafor;plerixafor;plerixafor
48 Efficacy and Safety Assessment of Oral LBH589 in Adult Patients With Advanced Soft TIssue Sarcoma After Pre-treatment Failure Completed NCT01136499 Phase 2 LBH589 (Panobinostat®)
49 Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma Completed NCT01614795 Phase 2 Temsirolimus
50 Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma Completed NCT00006102 Phase 2 becatecarin

Search NIH Clinical Center for Ewing Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: eye diseases

Genetic Tests for Ewing Sarcoma

Genetic tests related to Ewing Sarcoma:

# Genetic test Affiliating Genes
1 Ewing's Sarcoma 29 EWSR1
2 Abnormality of the Eye 29

Anatomical Context for Ewing Sarcoma

MalaCards organs/tissues related to Ewing Sarcoma:

41
Bone, Eye, Lung, T Cells, Endothelial, Kidney, Breast

Publications for Ewing Sarcoma

Articles related to Ewing Sarcoma:

(show top 50) (show all 586)
# Title Authors Year
1
EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. ( 29945296 )
2018
2
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. ( 29416716 )
2018
3
Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment. ( 29298256 )
2018
4
MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. ( 29263143 )
2018
5
Chemokine Expression Is Involved in the Vascular Neogenesis of Ewing Sarcoma: A Preliminary Analysis of the Early Stages of Angiogenesis in a Xenograft Model. ( 29895220 )
2018
6
Targeting Histone Deacetylase Activity to Arrest Cell Growth and Promote Neural Differentiation in Ewing Sarcoma. ( 29397557 )
2018
7
Programmed cell death ligand 1 (PD-L1) expression is not a predominant feature in Ewing sarcomas. ( 28868758 )
2018
8
Sinusoidal obstruction syndrome/veno-occlusive disease after high-dose intravenous busulfan/melphalan conditioning therapy in high-risk Ewing Sarcoma. ( 29335623 )
2018
9
EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. ( 29358035 )
2018
10
Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor in the Adrenal Gland of a Child. ( 29891750 )
2018
11
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. ( 29412642 )
2018
12
PAX7 Immunohistochemical Evaluation of Ewing Sarcoma and Other Small Round Cell Tumors. ( 29920735 )
2018
13
Author Correction: EWS-FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma. ( 29950716 )
2018
14
Beclin-1 knockdown decreases proliferation, invasion and migration of Ewing sarcoma SK-ES-1 cells via inhibition of MMP-9. ( 29435061 )
2018
15
Esophagitis associated with multimodality management of pediatric Ewing sarcoma of thorax. ( 29431250 )
2018
16
Age dependency of primary tumor sites and metastases in patients with Ewing sarcoma. ( 29856530 )
2018
17
Extra-Osseous Ewing Sarcoma of Sciatic Nerve Masquerading as Benign Nerve Sheath Tumor and Presented as Lumbar Radiculopathy: Case Report and Review of Literature. ( 29673820 )
2018
18
Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors. ( 28616785 )
2018
19
Detection of circulating tumor cells in liquid biopsy from Ewing sarcoma patients. ( 29386915 )
2018
20
Tumor suppressive ZBTB4 inhibits cell growth by regulating cell cycle progression and apoptosis in Ewing sarcoma. ( 29425745 )
2018
21
Successful Spontaneous Pregnancy after Treatment for Ewing Sarcoma including Sacrectomy. ( 29854509 )
2018
22
Gene expression changes associated with chemotherapy resistance in Ewing sarcoma cells. ( 29844902 )
2018
23
Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99. ( 29382926 )
2018
24
Radiotherapy Outcome for Pediatric Pelvic Ewing Sarcoma. ( 29848420 )
2018
25
Combined analysis of gene expression and genome binding profiles identified potential therapeutic targets of ciclopirox in Ewing sarcoma. ( 29328472 )
2018
26
Ewing sarcoma. ( 29977059 )
2018
27
Intracranial Ewing sarcoma: four pediatric examples. ( 29285586 )
2018
28
Ewing sarcoma. ( 29976985 )
2018
29
Preclinical Testing of an Oncolytic Parvovirus in Ewing Sarcoma: Protoparvovirus H-1 Induces Apoptosis and Lytic Infection In Vitro but Fails to Improve Survival In Vivo. ( 29865280 )
2018
30
MiR-107 suppresses cell proliferation and tube formation of Ewing sarcoma cells partly by targeting HIF-1I^. ( 29075999 )
2018
31
Eight-year follow-up after scapulectomy in a neonate with congenital Ewing sarcoma of the scapula. ( 29934281 )
2018
32
Unusual Radiographic Presentation of Primary Ewing Sarcoma of the Orbit. ( 29937126 )
2018
33
Ewing Sarcoma and the History of Similar and Possibly Related Small Round Cell Tumors: From Whence Have We Come and Where are We Going? ( 29911999 )
2018
34
Metachronous renal Ewing sarcoma/primitive neuroectodermal tumour in a survivor of Burkitt lymphoma. ( 29895547 )
2018
35
EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis. ( 29873416 )
2018
36
Prognostic value and functional role of ROCK2 in pediatric Ewing sarcoma. ( 29434937 )
2018
37
The Ewing sarcoma secretome and its response to activation of Wnt/beta-catenin signaling. ( 29386236 )
2018
38
EWS/ETS-driven Ewing Sarcoma requires BET bromodomain proteins. ( 29898995 )
2018
39
Primary Spinal Intradural Extraosseous Ewing Sarcoma in a Pediatric Patient: Case Report and Review of the Literature. ( 29804110 )
2018
40
Rare presentation of Ewing sarcoma metastasis to the sella and suprasellar cistern. ( 27816880 )
2017
41
Rare Ileal Ewing Sarcoma/Primitive Neuroectodermal Tumor on 18F-FDG PET/CT. ( 28806254 )
2017
42
Ewing Sarcoma of the Bone With EWS/FLI1 Translocation After Successful Treatment of Primary Osteosarcoma. ( 27918348 )
2017
43
Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth. ( 28847958 )
2017
44
Eribulin alone or in combination with the PLK1 inhibitor BI 6727 triggers intrinsic apoptosis in Ewing sarcoma cell lines. ( 28477025 )
2017
45
Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. ( 28429277 )
2017
46
Primary Ewing Sarcoma of the Mastoid: A Novel Case Mimicking Acute Mastoiditis. ( 29176463 )
2017
47
High-throughput RNAi screen in Ewing sarcoma cells identifies leucine rich repeats and WD repeat domain containing 1 (LRWD1) as a regulator of EWS-FLI1 driven cell viability. ( 27760381 )
2017
48
Matrix screen identifies synergistic combination of PARP inhibitors and nicotinamide phosphoribosyltransferase (NAMPT) inhibitors in Ewing sarcoma. ( 28899971 )
2017
49
Results for patients with sarcoma not otherwise specified and other diagnoses than Ewing sarcoma treated according to the Euro-EWING 99 trial. ( 28436593 )
2017
50
ROCK1-PredictedmicroRNAs Dysregulation Contributes to Tumor Progression in Ewing Sarcoma. ( 29270775 )
2017

Variations for Ewing Sarcoma

ClinVar genetic disease variations for Ewing Sarcoma:

6
(show all 46)
# Gene Variation Type Significance SNP ID Assembly Location
1 RDH12 NM_152443.2(RDH12): c.806_810delCCCTG (p.Ala269Glyfs) deletion Pathogenic rs386834261 GRCh37 Chromosome 14, 68196055: 68196059
2 RDH12 NM_152443.2(RDH12): c.806_810delCCCTG (p.Ala269Glyfs) deletion Pathogenic rs386834261 GRCh38 Chromosome 14, 67729338: 67729342
3 ABCC6 NM_001171.5(ABCC6): c.3389C> T (p.Thr1130Met) single nucleotide variant Pathogenic/Likely pathogenic rs63750459 GRCh37 Chromosome 16, 16256967: 16256967
4 ABCC6 NM_001171.5(ABCC6): c.3389C> T (p.Thr1130Met) single nucleotide variant Pathogenic/Likely pathogenic rs63750459 GRCh38 Chromosome 16, 16163110: 16163110
5 VPS13B NM_017890.4(VPS13B): c.2591C> A (p.Ser864Ter) single nucleotide variant Pathogenic rs140936527 GRCh37 Chromosome 8, 100286501: 100286501
6 VPS13B NM_017890.4(VPS13B): c.2591C> A (p.Ser864Ter) single nucleotide variant Pathogenic rs140936527 GRCh38 Chromosome 8, 99274273: 99274273
7 CACNA2D4 NM_172364.4(CACNA2D4): c.1882C> T (p.Arg628Ter) single nucleotide variant Uncertain significance rs200098356 GRCh37 Chromosome 12, 1969369: 1969369
8 CACNA2D4 NM_172364.4(CACNA2D4): c.1882C> T (p.Arg628Ter) single nucleotide variant Uncertain significance rs200098356 GRCh38 Chromosome 12, 1860203: 1860203
9 VPS13B NM_017890.4(VPS13B): c.6370_6371delAT (p.Met2124Valfs) deletion Pathogenic/Likely pathogenic rs748404277 GRCh37 Chromosome 8, 100712001: 100712002
10 VPS13B NM_017890.4(VPS13B): c.6370_6371delAT (p.Met2124Valfs) deletion Pathogenic/Likely pathogenic rs748404277 GRCh38 Chromosome 8, 99699773: 99699774
11 CNGA3 NM_001298.2(CNGA3): c.1688G> A (p.Arg563His) single nucleotide variant Pathogenic rs552069173 GRCh37 Chromosome 2, 99013321: 99013321
12 CNGA3 NM_001298.2(CNGA3): c.1688G> A (p.Arg563His) single nucleotide variant Pathogenic rs552069173 GRCh38 Chromosome 2, 98396858: 98396858
13 46;XX;inv(6)(p11.1q21)dn inversion Uncertain significance
14 CNGB3 NM_019098.4(CNGB3): c.1285delT (p.Ser429Leufs) deletion Pathogenic/Likely pathogenic rs776896038 GRCh37 Chromosome 8, 87645015: 87645015
15 CNGB3 NM_019098.4(CNGB3): c.1285delT (p.Ser429Leufs) deletion Pathogenic/Likely pathogenic rs776896038 GRCh38 Chromosome 8, 86632787: 86632787
16 ABCC6 NM_001171.5(ABCC6): c.4104delC (p.Asp1368Glufs) deletion Pathogenic rs72664237 GRCh38 Chromosome 16, 16154732: 16154732
17 ABCC6 NM_001171.5(ABCC6): c.4104delC (p.Asp1368Glufs) deletion Pathogenic rs72664237 GRCh37 Chromosome 16, 16248589: 16248589
18 GNAT2 NM_005272.3(GNAT2): c.906C> A (p.Tyr302Ter) single nucleotide variant Likely pathogenic GRCh37 Chromosome 1, 110146135: 110146135
19 GNAT2 NM_005272.3(GNAT2): c.906C> A (p.Tyr302Ter) single nucleotide variant Likely pathogenic GRCh38 Chromosome 1, 109603513: 109603513
20 CNGA3 NM_001298.2(CNGA3): c.107_110delACTC (p.His36Argfs) deletion Likely pathogenic rs749036398 GRCh37 Chromosome 2, 98994155: 98994158
21 CNGA3 NM_001298.2(CNGA3): c.107_110delACTC (p.His36Argfs) deletion Likely pathogenic rs749036398 GRCh38 Chromosome 2, 98377692: 98377695
22 IMPG2 NM_016247.3(IMPG2): c.1680T> A (p.Tyr560Ter) single nucleotide variant Pathogenic rs758291149 GRCh37 Chromosome 3, 100963495: 100963495
23 IMPG2 NM_016247.3(IMPG2): c.1680T> A (p.Tyr560Ter) single nucleotide variant Pathogenic rs758291149 GRCh38 Chromosome 3, 101244651: 101244651
24 CNGB3 NM_019098.4(CNGB3): c.1810C> T (p.Arg604Ter) single nucleotide variant Likely pathogenic rs200805087 GRCh38 Chromosome 8, 86579224: 86579224
25 CNGB3 NM_019098.4(CNGB3): c.1810C> T (p.Arg604Ter) single nucleotide variant Likely pathogenic rs200805087 GRCh37 Chromosome 8, 87591452: 87591452
26 RBP4 NM_006744.3(RBP4): c.248+1G> A single nucleotide variant Likely pathogenic rs111785373 GRCh38 Chromosome 10, 93600666: 93600666
27 RBP4 NM_006744.3(RBP4): c.248+1G> A single nucleotide variant Likely pathogenic rs111785373 GRCh37 Chromosome 10, 95360423: 95360423
28 TYR NM_000372.4(TYR): c.1037G> T (p.Gly346Val) single nucleotide variant Likely pathogenic rs773970123 GRCh38 Chromosome 11, 89227823: 89227823
29 TYR NM_000372.4(TYR): c.1037G> T (p.Gly346Val) single nucleotide variant Likely pathogenic rs773970123 GRCh37 Chromosome 11, 88960991: 88960991
30 RPGRIP1 NM_020366.3(RPGRIP1): c.2398G> A (p.Glu800Lys) single nucleotide variant Likely pathogenic rs565837539 GRCh37 Chromosome 14, 21794020: 21794020
31 RPGRIP1 NM_020366.3(RPGRIP1): c.2398G> A (p.Glu800Lys) single nucleotide variant Likely pathogenic rs565837539 GRCh38 Chromosome 14, 21325861: 21325861
32 NR2E3 NM_016346.3(NR2E3): c.305C> A (p.Ala102Asp) single nucleotide variant Likely pathogenic rs772881093 GRCh38 Chromosome 15, 71811825: 71811825
33 NR2E3 NM_016346.3(NR2E3): c.305C> A (p.Ala102Asp) single nucleotide variant Likely pathogenic rs772881093 GRCh37 Chromosome 15, 72104165: 72104165
34 NYX NM_022567.2(NYX): c.936C> G (p.Asn312Lys) single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 41474389: 41474389
35 NYX NM_022567.2(NYX): c.936C> G (p.Asn312Lys) single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 41333642: 41333642
36 RP2 NM_006915.2(RP2): c.43delT (p.Ser15Argfs) deletion Likely pathogenic GRCh37 Chromosome X, 46696578: 46696578
37 RP2 NM_006915.2(RP2): c.43delT (p.Ser15Argfs) deletion Likely pathogenic GRCh38 Chromosome X, 46837143: 46837143
38 CACNA1F NM_005183.3(CACNA1F): c.3628C> T (p.Gln1210Ter) single nucleotide variant Likely pathogenic rs782362725 GRCh37 Chromosome X, 49071548: 49071548
39 CACNA1F NM_005183.3(CACNA1F): c.3628C> T (p.Gln1210Ter) single nucleotide variant Likely pathogenic rs782362725 GRCh38 Chromosome X, 49215088: 49215088
40 CHM NM_000390.3(CHM): c.315-1536A> G single nucleotide variant Likely pathogenic GRCh37 Chromosome X, 85220593: 85220593
41 CHM NM_000390.3(CHM): c.315-1536A> G single nucleotide variant Likely pathogenic GRCh38 Chromosome X, 85965588: 85965588
42 AHI1 NC_000006.11: g.135759007_135762232del3226 deletion Likely pathogenic GRCh37 Chromosome 6, 135759007: 135762232
43 TRPM6 NC_000009.11: g.77388717_77398576del9860 deletion Likely pathogenic GRCh37 Chromosome 9, 77388717: 77398576
44 subset of 27 genes:PRRT2 GRCh37/hg19 16p11.2(chr16: 29656684-30197341) copy number gain Likely pathogenic GRCh37 Chromosome 16, 29656684: 30197341
45 AIFM3; CRKL; LZTR1; P2RX6; PI4KA; SERPIND1; SLC7A4; SNAP29; THAP7 GRCh37/hg19 22q11.21(chr22: 21081260-21431174) copy number gain Uncertain significance GRCh37 Chromosome 22, 21081260: 21431174
46 TRHR GRCh37/hg19 8q23.1(chr8: 109990022-110168343) copy number loss Uncertain significance GRCh37 Chromosome 8, 109990022: 110168343

Cosmic variations for Ewing Sarcoma:

9
(show all 46)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM1732355 H3F3A soft tissue,bone,sarcoma,NS c.103G>T p.G35W 1:226064454-226064454 37
2 COSM3908208 GNAQ soft tissue,bone,sarcoma,NS c.442C>T p.R148* 9:77815650-77815650 37
3 COSM3908209 soft tissue,bone,sarcoma,NS c.355C>T p.R119* 9:77815650-77815650 37
4 COSM43687 TP53 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 33
5 COSM11333 TP53 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 33
6 COSM6979022 SRC soft tissue,lung,sarcoma,NS c.205T>G p.S69A 20:37384358-37384358 33
7 COSM4774989 SH2B3 soft tissue,leg,sarcoma,NS c.232G>A p.E78K 12:111418377-111418377 33
8 COSM389868 RAC1 soft tissue,lung,sarcoma,NS c.476C>T p.A159V 7:6402343-6402343 33
9 COSM6979014 PTPRD soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 33
10 COSM6959031 PTCH1 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 33
11 COSM6979006 PBRM1 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 33
12 COSM6979021 PAK5 soft tissue,lung,sarcoma,NS c.41C>A p.P14Q 20:9644288-9644288 33
13 COSM6954536 NUP93 soft tissue,leg,sarcoma,NS c.116C>T p.A39V 16:56748363-56748363 33
14 COSM520 KRAS soft tissue,lung,sarcoma,NS c.35G>T p.G12V 12:25245350-25245350 33
15 COSM516 KRAS soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 33
16 COSM6979011 HGF soft tissue,lung,sarcoma,NS c.1711G>T p.V571L 7:81706333-81706333 33
17 COSM6959034 GPS2 soft tissue,lung,sarcoma,NS c.454C>T p.Q152* 17:7313932-7313932 33
18 COSM6979008 FOXP1 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 33
19 COSM2923082 ANKRD11 soft tissue,leg,sarcoma,NS c.2882G>T p.R961L 16:89283660-89283660 33
20 COSM121083 soft tissue,leg,sarcoma,NS c.220C>T p.Q74* 17:7675113-7675113 33
21 COSM6959030 soft tissue,lung,sarcoma,NS c.2921T>G p.F974C 9:95458260-95458260 33
22 COSM1640840 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 33
23 COSM6979007 soft tissue,lung,sarcoma,NS c.2834G>A p.R945H 3:52589201-52589201 33
24 COSM307279 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 33
25 COSM6979005 soft tissue,lung,sarcoma,NS c.2738G>A p.R913H 3:52589201-52589201 33
26 COSM2744872 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 33
27 COSM6979012 soft tissue,lung,sarcoma,NS c.4160C>T p.A1387V 9:8404587-8404587 33
28 COSM6979020 soft tissue,lung,sarcoma,NS c.1831+1G>T p.? 19:45353082-45353082 33
29 COSM1140136 soft tissue,lung,sarcoma,NS c.34G>T p.G12C 12:25245351-25245351 33
30 COSM6979017 soft tissue,lung,sarcoma,NS c.2573C>T p.A858V 9:8404587-8404587 33
31 COSM6979010 soft tissue,lung,sarcoma,NS c.1036G>T p.V346L 3:179203766-179203766 33
32 COSM6979009 soft tissue,lung,sarcoma,NS c.74A>G p.H25R 3:71198308-71198308 33
33 COSM3937613 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 33
34 COSM1154840 soft tissue,lung,sarcoma,NS c.533C>T p.A178V 7:6402343-6402343 33
35 COSM307282 soft tissue,leg,sarcoma,NS c.362A>G p.H121R 17:7674890-7674890 33
36 COSM6959033 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 33
37 COSM121082 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 33
38 COSM121084 soft tissue,leg,sarcoma,NS c.103C>T p.Q35* 17:7675113-7675113 33
39 COSM3388198 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 33
40 COSM6979016 soft tissue,lung,sarcoma,NS c.2930C>T p.A977V 9:8404587-8404587 33
41 COSM121081 soft tissue,leg,sarcoma,NS c.499C>T p.Q167* 17:7675113-7675113 33
42 COSM6979013 soft tissue,lung,sarcoma,NS c.2942C>T p.A981V 9:8404587-8404587 33
43 COSM307280 soft tissue,leg,sarcoma,NS c.641A>G p.H214R 17:7674890-7674890 33
44 COSM6959032 soft tissue,lung,sarcoma,NS c.2918T>G p.F973C 9:95458260-95458260 33
45 COSM307281 soft tissue,leg,sarcoma,NS c.245A>G p.H82R 17:7674890-7674890 33
46 COSM6979015 soft tissue,lung,sarcoma,NS c.2939C>T p.A980V 9:8404587-8404587 33

Copy number variations for Ewing Sarcoma from CNVD:

7 (show top 50) (show all 157)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13324 1 1 124300000 Deletion Ewing''s sarcoma
2 13741 1 1 27800000 Deletion Ewing''s sarcoma
3 16432 1 124300000 247249719 Gain Ewing''s sarcoma
4 16433 1 124300000 247249719 Gain Ewing''s sarcoma
5 16640 1 1286916 1536363 Loss Ewing''s sarcoma
6 17338 1 142400000 247249719 Gain Ewing''s sarcoma
7 17361 1 142565191 158296814 Gain AG1 Ewing''s sarcoma
8 20077 1 15300000 154800000 Gain Ewing''s sarcoma
9 20877 1 154978607 154979115 Gain HDGF Ewing''s sarcoma
10 21389 1 158408551 189951958 Gain FREB Ewing''s sarcoma
11 27410 1 208096981 208097464 Gain C1orf107 Ewing''s sarcoma
12 27922 1 215848737 215849264 Copy number GPATCH2 Ewing''s sarcoma
13 28256 1 220611046 220683633 Loss FBXO28 Ewing''s sarcoma
14 28623 1 224110806 224111244 Gain TMEM63A Ewing''s sarcoma
15 29204 1 228895774 228896323 Gain COG2 Ewing''s sarcoma
16 29247 1 229426179 229426672 Copy number C1orf131 Ewing''s sarcoma
17 29294 1 2300000 27800000 Deletion Ewing''s sarcoma
18 29735 1 234815741 234816376 Gain HEATR1 Ewing''s sarcoma
19 31804 1 3118000 5001000 Deletion Ewing''s sarcoma
20 31805 1 3118000 5001000 Deletion Ewing''s sarcoma
21 34220 1 53642491 53911866 Loss DMRTB1 Ewing''s sarcoma
22 35775 1 67181498 104009233 Loss SLC35D1 Ewing''s sarcoma
23 37996 1 9778925 10706826 Deletion APITD1 Ewing''s sarcoma
24 37997 1 9778925 10706826 Deletion CLSTN1 Ewing''s sarcoma
25 37998 1 9778925 10706826 Deletion CORT Ewing''s sarcoma
26 37999 1 9778925 10706826 Deletion CTNNBIP1 Ewing''s sarcoma
27 38000 1 9778925 10706826 Deletion DFFA Ewing''s sarcoma
28 38001 1 9778925 10706826 Deletion LZIC Ewing''s sarcoma
29 38002 1 9778925 10706826 Deletion NMNAT1 Ewing''s sarcoma
30 38003 1 9778925 10706826 Deletion PEX14 Ewing''s sarcoma
31 38004 1 9778925 10706826 Deletion PGD Ewing''s sarcoma
32 38005 1 9778925 10706826 Deletion RBP7 Ewing''s sarcoma
33 38141 10 1 135374737 Deletion Ewing''s sarcoma
34 41153 10 138206 135293404 Gain Ewing''s sarcoma
35 48491 11 1 52900000 Gain Ewing''s sarcoma
36 55430 11 52900000 134452384 Gain Ewing''s sarcoma
37 59789 11 777331 821974 Loss BM88 Ewing''s sarcoma
38 60445 11 86456481 127953177 Loss Ewing''s sarcoma
39 61420 12 1 132349534 Gain Ewing''s sarcoma
40 61533 12 1 35400000 Gain Ewing''s sarcoma
41 62737 12 111075038 111075556 Gain TRAFD1 Ewing''s sarcoma
42 63302 12 116955326 116955682 Copy number WSB2 Ewing''s sarcoma
43 64487 12 12873623 12874134 Gain DDX47 Ewing''s sarcoma
44 65323 12 1570852 1571348 Copy number FBXL14 Ewing''s sarcoma
45 66228 12 2670999 2671234 Deletion CACNA1C Ewing''s sarcoma
46 67041 12 35400000 132349534 Gain Ewing''s sarcoma
47 67472 12 41121456 41121979 Gain PPHLN1 Ewing''s sarcoma
48 68463 12 49967 52715434 Gain IQSEC3 Ewing''s sarcoma
49 68787 12 51501640 51502010 Copy number KRT79 Ewing''s sarcoma
50 69068 12 52981304 57130106 Gain Ewing''s sarcoma

Expression for Ewing Sarcoma

Search GEO for disease gene expression data for Ewing Sarcoma.

Pathways for Ewing Sarcoma

Pathways related to Ewing Sarcoma according to KEGG:

37
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

GO Terms for Ewing Sarcoma

Cellular components related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 perikaryon GO:0043204 8.8 CNGA3 ENO2 FUS

Biological processes related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell differentiation GO:0030154 9.73 ERG ETV1 ETV4 FLI1 IGF1R KIT
2 visual perception GO:0007601 9.26 ABCC6 CNGA3 IMPG2 RDH12
3 megakaryocyte development GO:0035855 9.16 FLI1 KIT
4 transcription by RNA polymerase II GO:0006366 9.1 ERG ETV1 ETV4 FLI1 POU5F1 WT1

Molecular functions related to Ewing Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.43 ERG ETV1 ETV4 FLI1 POU5F1 WT1
2 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 9.02 ERG ETV1 ETV4 FLI1 WT1

Sources for Ewing Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....